Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Cipla Ltd.
Change Company   
BSE Code 500087
ISIN Demat INE059A01026
Book Value 419.19
NSE Code CIPLA
Dividend Yield % 1.21
Market Cap 1070309.40
P/E 23.19
EPS 57.14
Face Value 2  
02-Feb-2026 Cipla informs about appointment of senior managem...
23-Jan-2026 Cipla's consolidated net profit drops 57% in Q3
21-Jan-2026 Cipla inks pact with ImmunoACT to commercialize t...
23-Dec-2025 Cipla launches orally inhaled insulin in India
19-Dec-2025 Cipla informs about updates
11-Dec-2025 Cipla moves up on launching ‘Yurpeak’
10-Dec-2025 Cipla launches ‘Yurpeak’
05-Dec-2025 Cipla completes acquisition of 100% stake in Inzp...
05-Dec-2025 Cipla gains on completing acquisition of 100% sta...
04-Dec-2025 Cipla launches therapy for Knee Osteoarthritis ‘C...
04-Dec-2025 Cipla gains on launching therapy for Knee Osteoar...
29-Nov-2025 Cipla launches integrated lung diagnostics, welln...
04-Nov-2025 Cipla to acquire Inzpera Healthsciences
30-Oct-2025 Cipla reports 4% rise in Q2 consolidated net prof...
30-Oct-2025 Cipla informs about financial results
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.